Avoiding Peripheral Iridotomy with ICL for Hyperopia
Yes, peripheral iridotomy can be avoided by using the newest FDA-approved phakic IOL that incorporates a central hole (port), which eliminates the need for peripheral iridectomy or iridotomy by minimizing the risk of pupillary block. 1
The Central Hole Design Solution
The key to avoiding peripheral iridotomy lies in selecting the appropriate ICL model:
Older ICL models (V4, V4b, V4c without central port) require a peripheral iridectomy or iridotomy to prevent pupillary block, typically performed 7-14 days before surgery using Nd:YAG laser. 1
Newer ICL models with central hole/port (EVO/EVO+) incorporate a central aqueous port that allows physiologic flow of aqueous humor, eliminating the requirement for preoperative peripheral iridotomy. 2
Evidence Supporting the Central Port Design
The central port design has been validated through multiple mechanisms:
Computational fluid dynamics modeling demonstrates that the Hole-ICL without laser iridotomy maintains adequate aqueous flow velocity (1.48 × 10⁻¹ mm/s at the crystalline lens center), which is substantially higher than conventional ICL with iridotomy (3.60 × 10⁻⁴ to 6.33 × 10⁻⁴ mm/s). 3
Clinical outcomes from the 3-year FDA prospective multicenter study (629 eyes) confirmed that no eyes experienced pupillary block requiring peripheral iridotomy or iridectomy, elevated IOP due to angle narrowing, or pigment dispersion with the EVO ICL central port design. 2
Clinical Advantages of Avoiding Iridotomy
By using the central port ICL design, you avoid several complications associated with peripheral iridotomy:
Reduced visual symptoms: No risk of postoperative glare and ghosting that can occur when iridotomies straddle the lid margin. 1
Lower complication rates: The central hole ICL demonstrates relatively lower incidence of high intraocular pressure, secondary glaucoma, and cataract formation compared to non-hole ICL designs. 4
Simplified surgical protocol: Eliminates the need for a separate preoperative laser procedure and associated patient visits. 2
Important Caveat
While the evidence presented focuses primarily on myopia correction, the same principles apply to hyperopic ICL correction. The American Academy of Ophthalmology guidelines explicitly state that the newest FDA-approved phakic IOL with central hole eliminates the need for peripheral iridectomy or iridotomy regardless of the refractive indication. 1
The practical recommendation: For hyperopic ICL implantation, specifically request and use the EVO or EVO+ ICL models with the central port design to avoid the need for peripheral iridotomy entirely. 2